{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.4","upperLimit":"42.3","value":"36.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"NUMBER","populationDescription":"Cohort 2 ITT Population","reportingStatus":"POSTED","timeFrame":"1-year","title":"Percentage of Participants Alive at 1-year","type":"SECONDARY","unitOfMeasure":"percentage of participants"}